SEC Form 4 · accession 0001209191-17-002976
Dare Bioscience, Inc. · DARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Eliasof
Officer — SVP, Chief Scientific Officer
Period of report
Jan 5, 2017
Accepted (ET)
Jan 9, 2017 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401914
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.82 | Jan 5, 2017 | A | 60,000 | A | — | Jan 4, 2027 | Common Stock | 60,000 | 60,000 | D |
| Stock Option (right to buy)F2 | $0.82 | Jan 5, 2017 | A | 100,000 | A | — | Jan 4, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017.
- F2This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.